Navigation Links
DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6(R) Cell Line Proteins
Date:6/24/2008

LEIDEN, Netherlands and PARSIPPANY, N.J., June 25 /PRNewswire/ -- DSM Biologics and Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Avid Bioservices, Inc. of Tustin, California to join their Vendor Network. Under the terms of the agreement, Avid will be a pre-approved contract manufacturer (CMO) for licensees of the PER.C6(R) cell line located in the western U.S. Avid is the first U.S.-based contract manufacturer to be awarded this status.

Karen King, president of DSM Biologics notes, "We are confident that Avid's excellent reputation and service level will be instrumental in making the PER.C6(R) technology available to licensees on the West Coast, bringing our technology to a wider regional base as we continue to grow globally."

Steven W. King, president of Avid Bioservices added, "We are honored to achieve the distinction of being the first pre-approved U.S.-based CMO to manufacture proteins and antibodies using the PER.C6(R) cell line. The PER.C6(R) technology is recognized throughout our industry as providing important advantages compared to other platforms, including serum-free medium, scalability and high productivity levels making the system an ideal fit for Avid."

Crucell and DSM last week announced a breakthrough in the production of IgG antibodies using Crucell's PER.C6(R) technology. By employing the PER.C6(R) human cell line and DSM's proprietary XD(TM) technology, a record yield of over 27 grams per liter has been achieved.

The PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

Other terms of the agreement were not disclosed. Avid B
'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
2. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
3. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
4. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
5. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. RNs at Nine Catholic Healthcare West Hospitals Reach Agreement on New Master Pact
8. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
9. Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
10. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
11. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... The American,electorate has changed the course of history by ... that the messages of the Obama,presidency will be broader ... includes women. Lawrence Summers is not an appropriate choice ... The,contributions of science are important to the health of ...
... medications prove worth against the condition, doctors say , , ... new ways to use exercise and medications to manage ... a condition that affects more than 5 million Americans. ... percent reduction in death or hospitalization rates from any ...
... significant factors affect the spread of infectious diseases, including ... malaria" is a term coined by researchers to explain ... as the United States and Europe, which some scientists ... transmitted when a mosquito infected with the disease bites ...
... -- Pantheon China Acquisition,Corp. ("Pantheon", OTC Bulletin ... 2008 it entered into an agreement and ... Agreement") with China Cord Blood,Services Corporation ("CCBS") ... Company Limited ("Golden Meditech", Stock Code: 8180.HK),(collectively, ...
... VIEW, Calif., Nov. 11 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... will present at the following investor conferences,in November and December:, ... The St. Regis Hotel 2 East 55th Street, New ... p.m. ET, 20th Annual Piper Jaffray Health Care Conference ...
... troubling trend , , TUESDAY, Nov. 11 (HealthDay News) -- ... for heart disease is slowing considerably. , In fact, ... starting at the beginning of the millennium. , "Dramatic ... of time, but now they,re leveling off," said Dr. ...
Cached Medicine News:Health News:Statement From the Rosalind Franklin Society: Lawrence Summers Not the Right Choice for Cabinet Position in Obama Administration 2Health News:Gains Against Heart Failure Reported 2Health News:Gains Against Heart Failure Reported 3Health News:'Airport malaria' -- cause for concern in the US 2Health News:Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC 2Health News:Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC 3Health News:Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC 4Health News:Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC 5Health News:Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC 6Health News:Pantheon China Acquisition Corp. to Acquire China Cord Blood Services Corporation - Extension Proxy Filed With SEC 7Health News:Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 2Health News:Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts 3Health News:After Decades, Decreases in Heart Risk Factors Level Off 2
(Date:1/15/2014)... , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ... Summary,Although the past decade has seen ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ... of the very important aspects in today,s ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ... reductions in body fat content and preserved lean ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... 29, 2011 Konica Minolta Sensing Americas, Inc. (KMSA), ... light and shape, announces the launch of its next ... pharmaceutical industry at the 2011 Interphex show March 29-31 ... (Photo: http://photos.prnewswire.com/prnh/20100714/NY35146 ) ...
... Oral antiplatelet therapy Effient® (prasugrel) has been ... a Class I recommended treatment option for patients ... chest pain at rest (unstable angina) or non-ST ... type of heart attack that that does not ...
Cached Medicine Technology:Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 2Konica Minolta Sensing Announces CM-5 Spectrophotometer to Pharmaceutical Industry at Interphex 2011 3Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 2Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 3Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 4Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 5Effient® Added to Updated ACCF/AHA Clinical Guidelines for ACS-PCI Patients with Unstable Angina and Non-ST Segment Myocardial Infarction 6
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: